Introduction: Johnson & Johnson's Highly Anticipated New Autoimmune Therapy
Recently, the NMPA issued a public notice regarding Johnson & Johnson's nicalimab injection (trade name: Anliwei®）granted marketing approval, in combination with standard therapy, for the treatment of adult and adolescent patients aged over 12 years with autoantibody-positive generalized myasthenia gravis (gMG). This marks another significant global milestone for nipocalimab following its FDA approval in April last year and subsequent approval by the European Commission, and also heralds the arrival of a strong new competitor in China's precision treatment landscape for gMG.Image Source: NMPA Official WebsiteIn August 2020, Johnson & Johnson announced the acquisition of Momenta Pharmaceuticals for approximately $6.5 billion, with the core target being this investigational FcRn antibody. On April 30, 2025, nipocalimab became the first to receive U.S. FDA approval (brand name IMAAVY®), indicated for the treatment of patients aged 12 years and older with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis. Subsequently, the European Commission also granted marketing authorization for the drug in Europe. Nipocalimab has now been successfully approved in China, taking only approximately one year from submission to approval—a remarkably swift pace.▲ Nicalizumab Global Launch TimelineImage source: Yaozhi Data - Global Drug Analysis SystemNotably, nipocalimab is currently the first and only FcRn antagonist approved in China for patients with gMG who test positive for both anti-AChR and anti-MuSK antibodies. Furthermore, its indication covers patients aged 12 years and older, marking a first among similar marketed products.For a long time, therapeutic options for gMG have been relatively limited. Although traditional cholinesterase inhibitors, glucocorticoids, and immunosuppressants remain foundational treatment regimens, they are characterized by a slow onset of action, substantial adverse effects, and a considerable proportion of patients still fail to achieve satisfactory disease control. In recent years, driven by a deeper understanding of the pathogenesis of gMG, targeted biologics have begun to reshape the treatment landscape.In recent years, targeted therapy for generalized myasthenia gravis (gMG) in China has entered a stage of concurrent advancement across multiple mechanisms. In 2023, eculizumab (Soliris®) and Efgartigimod alfa (Vyvgart®) were successively approved in China for gMG, among which efgartigimod became the first FcRn antagonist approved in China. Subsequently, rozanolixizumab (Youdige®), relimab (Velirib®), telitacicept (Tai'ai®) and Zelukebulun Sodium (Zhuobeike)®) were successively approved in 2025; in 2026, inebilizumab (Xinyue®) further joins the treatment portfolio in China.Data Source: Yaozhi Data - Global Drug Analysis SystemFor the broader FcRn therapeutic landscape, the approval of nipocalimab further validates the clinical value and commercial potential of this target. With efgartigimod, rozanolixizumab, and nipocalimab establishing a "tripartite competitive landscape" in China, alongside the advancement of more investigational drugs, gMG treatment is transitioning from an era of "limited available therapies" to a new stage of "multiple treatment options." Ultimately, patients will be the greatest beneficiaries of this intensifying competition.Disclaimer: This article is provided solely for informational purposes and does not represent the views of this platform. It is not intended as a treatment recommendation. For guidance on treatment plans,Please seek medical treatment at a licensed hospital. For any issues regarding the content, copyright, or other related matters, please leave a message on this platform. We will verify and address them promptly.
Responsible Editor | Xiao ErReprint Permission | Teacher Chen 17308362010 (WeChat: same)
Related Tags:Johnson & Johnson
0
0
